Updates on Depression among Cancer Patients

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".

Deadline for manuscript submissions: 28 April 2024 | Viewed by 616

Special Issue Editors


E-Mail Website
Guest Editor
School of Nursing, Department of Nursing, National Taiwan University Hospital, Taipei City, Taiwan
Interests: oncology nursing; palliative care nursing; chronic disease nursing; health behavior research

E-Mail Website
Guest Editor
School of Nursing, Graduate Institute of Nursing, China Medical University, Taichung City, Taiwan
Interests: oncology psychology; oncology care; mind-body therapy; stress neuroendocrine response; interventional research; systematic review; meta-analysis

E-Mail Website
Guest Editor
IRCCS Istituto Giovanni Paolo II, Bari, Italy
Interests: oncology psychology; oncology care; mind-body well-being; stress neuroendocrine linkage; interventional research; systematic review; meta-analysis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleauges,

This Special Issue aims to provide a comprehensive update on the topic of depression among cancer patients. It seeks to explore the latest research, advancements, and insights into understanding and managing depression in individuals diagnosed with cancer. By bringing together experts and researchers in the field, this Special Issue aims to shed light on the complex relationship between cancer and depression, contributing to improved patient care and mental health outcomes.

The scope of this Special Issue encompasses a broad range of topics related to depression among cancer patients, including but not limited to:

  1. Prevalence and risk factors of depression in cancer patients;
  2. Impact of depression on cancer prognosis and treatment outcomes;
  3. Psychological interventions and psychotherapy for managing depression in cancer patients;
  4. Pharmacological approaches and novel treatments for depression in cancer care;
  5. Role of social support and psychosocial interventions in alleviating depression symptoms;
  6. Comorbidity of depression and anxiety in cancer patients;
  7. Impact of depression on quality of life and survivorship in cancer patients;
  8. Understanding the neurobiological mechanisms underlying depression in cancer.

We look forward to your valuable contributions and collective efforts in advancing the knowledge and care for depression among cancer patients.

Prof. Dr. Wen-Yu Hu
Dr. Yun-Chen Chang
Dr. Elsa Vitale
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • depression
  • cancer patients
  • mental health
  • psycho-oncology
  • treatment
  • psychosocial interventions
  • survivorship
  • comorbidity
  • quality of life
  • neurobiology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 623 KiB  
Review
Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon
by Val Bellman
Cancers 2024, 16(9), 1702; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16091702 (registering DOI) - 27 Apr 2024
Viewed by 128
Abstract
Despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through Oregon’s Measure 109 in 2020, significant challenges have impeded its implementation. This review synthesizes the empirical data supporting the utilization of psilocybin therapy for addressing cancer-related depression, [...] Read more.
Despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through Oregon’s Measure 109 in 2020, significant challenges have impeded its implementation. This review synthesizes the empirical data supporting the utilization of psilocybin therapy for addressing cancer-related depression, including an evaluation of its purported benefits and potential adverse effects. It provides a comprehensive examination of therapeutic strategies, dosing regimens, and barriers to ensuring responsible and equitable access. Salient issues explored include the development of ethical protocols, integration within healthcare systems, ensuring statewide availability, resolving legal ambiguities, and defining clinical standards. Oregon’s pioneering role serves as a case study, highlighting the necessity of addressing regulatory, logistical, and ethical obstacles to ensure the establishment of rigorous and equitable psilocybin care models. Full article
(This article belongs to the Special Issue Updates on Depression among Cancer Patients)
Show Figures

Figure 1

Back to TopTop